Comienzos
keyboard_arrow_right
keyboard_arrow_right
ACT treats fourth individual in U.
Reports

ACT treats fourth individual in U.

Further information about patient eligibility for ACT’s SMD research and the concurrent research in the U.S. And Europe can be found at with the following Identifiers: NCT01345006 , NCT01344993 , and NCT01469832 .. ACT treats fourth individual in U.S. Scientific trial for Stargardt’s Macular Dystrophy Advanced Cellular Technology, Inc. , a innovator in the field of regenerative medicine, today announced treatment of the fourth patient, the 1st in the second individual cohort, in its U.S. Clinical trial for Stargardt’s Macular Dystrophy . On Wednesday The medical procedures was performed, 11 at Wills Vision Institute in Philadelphia July, by a surgical group lead by Carl D.Friday On, the Fluoride Actions Network submitted its responses to the Section of Health and Human Services on its proposal to lessen the amount of fluoride in drinking water. Science clearly implies that even as of this level fluoride remains bad for many Americans. FAN advises HHS to stop fluoridation since it is unnecessary completely, unethical, the benefits exaggerated wildly, and the risks minimized. Find FAN’s submission to HHS at – It’s important that HHS receive as much comments as possible. Please sign the web message to HHS stating support for FAN’s submission – just go to: or write your own comments.